Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Y-90 clivatuzumab tetraxetan - Immunomedics

X
Drug Profile

Y-90 clivatuzumab tetraxetan - Immunomedics

Alternative Names: 90Y-clivatuzumab tetraxetan; 90Y-hPAM4; 90y-Hpama4; Clivatucyn; Clivatuzumab; Clivatuzumab tetraxetan; Clivatuzumab tetraxetan Y-90; Clivatuzumab Y-90; hPAM4-Cide; hPAM4-DOTA; Humanised monoclonal antibody PAM4 Y-90; IMMU-107; Monoclonal antibody PAM4-Y-90; Pan-Cide; Y-90 clivatuzumab; Yttrium-(90Y) clivatuzumab tetraxetan; Yttrium-90 clivatuzumab tetraxetan; Yttrium-90 labelled monoclonal antibody PAM4

Latest Information Update: 27 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 18 Jan 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy) in USA and Germany (IV), because not listed on Immunomedics pipeline, January 2018
  • 18 Jan 2018 Discontinued - Phase-III for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, France, Belgium, Israel, Canada, Spain, Austria and USA (IV), further to negative results from the PANCRIT® 1 trial
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top